# Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

> **NCT07110246** · PHASE2 · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 96 (estimated)

## Conditions studied

- BRAF V600 Mutation
- Low-grade Glioma
- Low Grade Glioma of Brain
- Recurrent Low Grade Glioma

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib
- **PROCEDURE:** Magnetic Resonance Imaging (MRI)
- **PROCEDURE:** Specimen Collection
- **PROCEDURE:** Optional Lumbar puncture

## Key facts

- **NCT ID:** NCT07110246
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-07
- **Primary completion:** 2032-03-31
- **Final completion:** 2032-03-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07110246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07110246, "Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07110246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*